Arena Pharmaceuticals, Inc. (ARNA)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Arena Pharmaceuticals, Inc. (ARNA) trades at $99.99 with AI Score 53/100 (Grade B). Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative medicines for various diseases. Sector: Healthcare.
Price live · AI analysis from May 10, 2026Analyst Coverage for ARNA: ARNA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ARNA against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
ARNA: 3/7 perspectives are bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Arena Pharmaceuticals, Inc. (ARNA) Healthcare & Pipeline Overview
Arena Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing novel therapeutics with a strong focus on pharmacology and pharmacokinetics, positioning itself as a key player in the biotechnology sector with a diverse clinical pipeline.
What Is the Investment Thesis for ARNA?
Arena Pharmaceuticals, Inc. presents a compelling investment thesis driven by its diverse clinical pipeline and strategic partnerships. The company is currently advancing Etrasimod through multiple Phase III trials, with potential market entries in ulcerative colitis and atopic dermatitis expected in the coming years. Additionally, the ongoing development of Olorinab and APD418 could further enhance revenue streams, as these therapies target significant market opportunities in irritable bowel syndrome and acute heart failure, respectively. The acquisition by Pfizer provides Arena with enhanced financial stability and operational support, potentially accelerating its growth trajectory. However, investors should remain cautious of the inherent risks associated with drug development, including regulatory hurdles and market competition.
Based on FMP financials and quantitative analysis
ARNA Key Highlights
- Gross margin of 100.0% reflects the company's focus on high-value biopharmaceutical products.
- Profit margin of -1149244.4% indicates significant investment in R&D and operational costs.
- Beta of 0.55 suggests lower volatility compared to the broader market.
- No dividend yield as the company reinvests earnings into clinical development.
- Employee count of 448 demonstrates a dedicated workforce focused on innovation.
Who Are ARNA's Competitors?
ARNA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ROIV Roivant Sciences Ltd. | $35.39 | +0.74% | $25.45B | 39 |
| RCM R1 RCM Inc. | $14.31 | +0.00% | $6.04B | 54 |
| ISEE IVERIC bio, Inc. | $39.95 | +0.38% | $5.51B | 47 |
| MRTX Mirati Therapeutics, Inc. | $58.70 | -0.17% | $4.12B | 53 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ARNA's Key Strengths?
- Robust pipeline with multiple candidates in advanced clinical stages.
- Strong collaboration with Pfizer providing financial and operational support.
- High gross margin potential due to focus on innovative therapies.
What Are ARNA's Weaknesses?
- Negative profit margin indicating high R&D expenditures.
- Dependence on successful clinical trial outcomes for revenue generation.
- Limited product portfolio until candidates receive regulatory approval.
What Could Drive ARNA Stock Higher?
- Potential market approval for Etrasimod in ulcerative colitis and atopic dermatitis expected in 2026.
- Phase II trials for Olorinab and APD418, with data readouts anticipated in the near future.
- Strategic collaborations with Pfizer and other partners enhancing research capabilities.
What Are the Key Risks for ARNA?
- Negative return on equity (-70.8%) — the business is not currently generating profit on shareholder capital.
- Regulatory challenges could delay the approval of key drug candidates.
- High R&D costs may impact profitability in the short term.
- Competitive pressures from other biotechnology firms may affect market share.
What Are the Growth Opportunities for ARNA?
- Expansion of Etrasimod: Etrasimod is currently in multiple Phase III trials for ulcerative colitis and atopic dermatitis, with potential market approval expected in 2026. The global ulcerative colitis market is projected to reach $8.4 billion by 2027, presenting a significant revenue opportunity for Arena as it seeks to capture market share with this innovative therapy.
- Development of Olorinab: Olorinab is in Phase IIb trials for abdominal pain associated with irritable bowel syndrome, a condition affecting approximately 10-15% of the global population. The IBS market is anticipated to grow to $2.6 billion by 2025. Successful trial outcomes could position Arena favorably within this lucrative segment.
- Advancements in APD418: The Phase II clinical trial for APD418, targeting acute heart failure, aims to address a critical unmet need in a market projected to exceed $20 billion by 2026. If successful, this therapy could significantly enhance Arena's portfolio and revenue potential.
- Collaboration with Pfizer: As a subsidiary of Pfizer, Arena benefits from enhanced resources and expertise, facilitating accelerated development timelines and increased market access for its therapeutic candidates. This partnership may lead to strategic collaborations that further expand its pipeline.
- Market for Pulmonary Arterial Hypertension: Ralinepag (APD811) is in Phase III trials for pulmonary arterial hypertension, a condition with a growing market expected to reach $7.4 billion by 2026. Arena's focus on this area could yield substantial returns if the drug receives regulatory approval.
What Opportunities Does ARNA Have?
- Growing market for chronic disease therapies presents significant revenue potential.
- Expansion into international markets through partnerships and collaborations.
- Potential for licensing agreements post-approval to enhance revenue streams.
What Threats Does ARNA Face?
- Intense competition from other biotechnology firms and pharmaceutical companies.
- Regulatory hurdles and potential delays in drug approvals.
- Market volatility affecting funding and investment in R&D.
What Are ARNA's Competitive Advantages?
- Strong pipeline of investigational drugs targeting high unmet medical needs.
- Strategic partnerships with established pharmaceutical companies like Pfizer.
- Expertise in pharmacology and pharmacokinetics providing a competitive edge in drug development.
What Does ARNA Do?
Founded in 1997, Arena Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in San Diego, California. The company was established with the vision of creating innovative medicines that leverage advanced pharmacological and pharmacokinetic principles to address unmet medical needs. Over the years, Arena has developed a robust pipeline of investigational drugs targeting various conditions, including gastrointestinal disorders, dermatological conditions, and cardiovascular diseases. The company’s lead product candidate, Etrasimod (APD334), is currently undergoing multiple clinical trials, including Phase III trials for ulcerative colitis and atopic dermatitis, as well as Phase II trials for Crohn's disease and alopecia areata. Additionally, Arena is developing Olorinab (APD371) for abdominal pain associated with irritable bowel syndrome and APD418 for acute heart failure, among other candidates. The company has formed strategic collaborations with notable partners such as United Therapeutics Corporation and Boehringer Ingelheim, enhancing its research capabilities and market reach. In March 2022, Arena Pharmaceuticals became a subsidiary of Pfizer Inc., which has provided additional resources and support for its ongoing clinical programs. With a dedicated workforce of 448 employees, Arena is committed to advancing its pipeline and delivering innovative therapies to patients worldwide.
What Products and Services Does ARNA Offer?
- Develop novel biopharmaceutical products targeting chronic diseases.
- Conduct clinical trials to evaluate the safety and efficacy of investigational drugs.
- Collaborate with other pharmaceutical companies to enhance research capabilities.
- Leverage advanced pharmacological principles to create innovative therapies.
- Focus on multiple therapeutic areas including gastrointestinal, dermatological, and cardiovascular conditions.
How Does ARNA Make Money?
- Revenue generated through the development and commercialization of biopharmaceutical products.
- Collaborative agreements with other companies to share research and development costs.
- Potential licensing agreements for successful therapies post-approval.
- Investment in clinical trials to advance product candidates toward market approval.
What Industry Does ARNA Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in drug discovery and personalized medicine. The global biotechnology market is projected to reach $2.44 trillion by 2028, with a CAGR of 15.83% from 2021 to 2028. Within this landscape, Arena Pharmaceuticals, Inc. is positioned as a key player, focusing on developing targeted therapies for chronic diseases. The competitive landscape includes companies like Roivant Sciences Ltd. and Mirati Therapeutics, which are also pursuing innovative treatment options, creating a dynamic environment for growth and collaboration.
Who Are ARNA's Key Customers?
- Healthcare providers and hospitals seeking innovative treatment options.
- Patients suffering from chronic diseases requiring novel therapies.
- Pharmaceutical partners engaged in collaborative research and development.
Company Profile
Arena Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Amit Munshi. ARNA has traded publicly since 2000.
ARNA Valuation & Market Position
Relative to its peer group, ARNA's quantitative score of 53/100 is roughly in line with the peer average of 54/100.
ROE -71%Key Financial Metrics
Return on equity for Arena Pharmaceuticals, Inc. stands at -70.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -79.1%, showing how much profit it generates from its asset base. A current ratio of 8.59 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -11.3%, the inverse of the P/E and a quick read on earnings relative to price.
ARNA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Robust pipeline with multiple candidates in advanced clinical stages.
- Strong collaboration with Pfizer providing financial and operational support.
- High gross margin potential due to focus on innovative therapies.
- Upcoming: Potential market approval for Etrasimod in ulcerative colitis and atopic dermatitis expected in 2026.
Bear Case
- Negative profit margin indicating high R&D expenditures.
- Dependence on successful clinical trial outcomes for revenue generation.
- Limited product portfolio until candidates receive regulatory approval.
- Potential: Regulatory challenges could delay the approval of key drug candidates.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ARNA Latest News
No recent news available for ARNA.
ARNA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ARNA.
Price Targets
Wall Street price target analysis for ARNA.
ARNA MoonshotScore
What does this score mean?
The MoonshotScore rates ARNA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Amit Munshi
CEO
Amit Munshi has extensive experience in the biopharmaceutical industry, having held various leadership roles in both public and private companies. He has a strong track record in advancing drug development and commercialization strategies, contributing to the growth of several biotechnology firms. Munshi holds a degree in economics from the University of California, Berkeley, and an MBA from Harvard Business School.
Track Record: Under Amit Munshi's leadership, Arena Pharmaceuticals has successfully advanced its clinical pipeline, culminating in the acquisition by Pfizer in 2022. His strategic vision has positioned the company for growth in the competitive biopharmaceutical landscape.
ARNA Healthcare Stock FAQ
What does Arena Pharmaceuticals, Inc. do?
Arena Pharmaceuticals, Inc. is a biopharmaceutical company that develops innovative medicines for chronic diseases. The company focuses on creating novel therapeutic solutions through its extensive clinical pipeline, which includes drugs targeting conditions such as ulcerative colitis, Crohn's disease, and pulmonary arterial hypertension.
What is Arena Pharmaceuticals, Inc.'s drug pipeline status?
Arena Pharmaceuticals, Inc. has a diverse pipeline of investigational drugs in various clinical stages. Key candidates include Etrasimod, which is in Phase III trials for ulcerative colitis and atopic dermatitis, and Olorinab, currently in Phase IIb trials for irritable bowel syndrome. The company is also advancing APD418 for acute heart failure and ralinepag for pulmonary arterial hypertension.
What are the main risks for ARNA?
Arena Pharmaceuticals, Inc. faces several risks, including regulatory hurdles that could delay the approval of its drug candidates, high research and development costs impacting short-term profitability, and competitive pressures from other biotechnology firms that may affect its market position. These factors necessitate careful monitoring as the company progresses through its clinical trials.
What are the key factors to evaluate for ARNA?
Arena Pharmaceuticals, Inc. (ARNA) holds an AI score of 53/100 (moderate). Not financial advice.
How frequently does ARNA data refresh on this page?
ARNA prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ARNA's recent stock price performance?
Arena Pharmaceuticals, Inc. (ARNA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Robust pipeline with multiple candidates in advanced clinical stages. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ARNA overvalued or undervalued right now?
Valuing Arena Pharmaceuticals, Inc. (ARNA) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying ARNA?
Before investing in Arena Pharmaceuticals, Inc. (ARNA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information and may be subject to change.